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Abstract
Spermatid specific thioredoxin-3 (SPTRX3 or TXNDC8) is a testis/male germ line specific member of thioredoxin family that
accumulates in the superfluous cytoplasm of defective human spermatozoa. We hypothesized that semen levels of SPTRX3
are reflective of treatment outcome in assisted reproductive therapy (ART) couples treated by in vitro fertilization (IVF) or
intracytoplasmic sperm injection (ICSI). Relationship between SPTRX3 and treatment outcome was investigated in 239
couples undergoing ART at an infertility clinic. Sperm content of SPTRX3 was evaluated by flow cytometry and
epifluorescence microscopy, and correlated with clinical semen analysis parameters, and data on embryo development and
pregnancy establishment. High SPTRX3 levels (.15% SPTRX3-positive spermatozoa) were found in 51% of male infertility
patients (n = 72), in 20% of men from couples with unexplained, idiopathic infertility (n = 61) and in 14% of men from
couples previously diagnosed with female-only infertility (n = 85). Couples with high SPTRX3 produced fewer two-
pronuclear zygotes and had a reduced pregnancy rate (19.2% pregnant with .15% SPTRX3-positive spermatozoa vs. 41.2%
pregnant with ,5% SPTRX3-positive sperm; one-sided p,0.05). The average pregnancy rate of all 239 couples was 25.1%.
Live birth rate was 19.2% and lowest average SPTRX3 levels were found in couples that delivered twins. Men with .15% of
SPTRX3-positive spermatozoa, a cutoff value established by ROC analysis, had their chance of fathering children by IVF or
ICSI reduced by nearly two-thirds. The percentage of SPTRX3-positive spermatozoa had predictive value for pregnancy after
ART. Gradient purification and sperm swim-up failed to remove all SPTRX3-positive spermatozoa from semen prepared for
ART. In summary, the elevated semen content of SPTRX3 in men from ART couples coincided with reduced incidence of
pregnancy by IVF or ICSI, identifying SPTRX3 as a candidate biomarker reflective of ART outcome.
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Introduction
Infertility and the pursuant assisted reproductive therapies
(ART) are on rise worldwide. At the same time, oocyte/embryo
culture and manipulation technologies, and the diagnostic
techniques for female infertility have been advancing steadily.
On the contrary, the andrological aspect of infertile couple
evaluation still relies mostly on traditional, microscopy based
semen analysis, in addition to clinical examinations, hormonal
profiles, and cytogenetic and Yq microdeletion profiles. To some
extent, the assessment of the DNA fragmentation or chromatin
damage, associated with oxidative stress, apoptosis, or male genital
tract infection are used as diagnostic tools. Exposure to xenobiotics
and advanced paternal age are possible risk factors associated with
infertility. Sperm parameters can be measured in specialized
laboratories by the DNA-integrity based assays such as SCSA [1],
Comet [2] and TUNEL [3], but the value of such exploration is
uncertain for the moment [4]. As the repertoire of flow cytometric
semen evaluation methods increases, the challenge is on to find
new tools and fertility markers to reliably diagnose human male
infertility [5]. In addition to DNA fragmentation-based methods,
mitochondrial membrane potential probes [6], lectins [7], viability
stains [8], apoptosis-detecting probes [9], and antibodies against
proteins present predominantly in normal or defective spermato-
zoa are being adapted for flow cytometric semen analysis
(reviewed in [10]).
Thioredoxins (TRX) are a class of redox proteins that function
as general protein oxidoreductases by the reversible oxidation of
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the cysteine residues of their active site whose conserved sequence
is Cys-Gly-Pro-Cys. Thioredoxins are maintained in their reduced
active form by the flavoprotein thioredoxin reductase (TRXR) at
the expense of the reducing power of NADPH [11]. The functions
of thioredoxins are typically wide, mostly relying on their redox
capabilities, including antioxidant defense, modulation of cell
growth and differentiation, regulation of apoptosis and activation
of membrane ion channels, among others [11,12].
Besides ubiquitous thioredoxins found both in cytoplasm and
mitochondrial matrix in all cell types, mammals are equipped with
an additional set of thioredoxins with an expression pattern
restricted to male germ cells [13]. One of such thioredoxins is
Spermatid-Specific Thioredoxin 3 [SPTRX3; HUGO nomencal-
ture-TXNDC8 (thioredoxin domain containing 8)]. This thior-
edoxin is initially observed in the Golgi apparatus of pachytene
spermatocytes; it is later retained post-meiotically in round
spermatids in close association with the developing acrosomal
granule, suggesting a function in acrosomal biogenesis [14]. Once
the acrosome is formed, the residual SPTRX3 accumulates in the
cytoplasmic lobe of the elongating spermatids ready to be
discharged in the form of residual bodies. Interestingly, SPTRX3
remains undetectable in fully differentiated normal spermatozoa of
various animal species, but is retained in the superfluous cytoplasm
found filling the nuclear vacuoles and wrapping around the sperm
tail midpieces in morphologically aberrant human spermatozoa
[14,15]. A dual flow cytometric trial revealed a robust positive
correlation between sperm levels of SPTRX3 and ubiquitin (a
validated defective sperm biomarker [16]) in a cohort of 19
infertile and 5 fertile subjects [14]. A subsequent study used
ImageStream technology combining flow cytometry and light
microscopy, to directly demonstrate that the flow cytometric
events with high SPTRX3 induced fluorescence are defective
spermatozoa with excess cytoplasm and/or nuclear vacuoles [15].
In addition to spermatid specific thioredoxins 1, 2 and 3
[14,17,18,19], the residual cytoplasm carries cytoplasmic enzymes
such as glucose-6-phosphate dehydrogenase [20], superoxide
dismutase [21], lactic acid dehydrogenase [22] and creatine
phosphokinase [20,23]. Retention of residual cytoplasm coincides
with impaired sperm function in humans [24,25]. In most
mammals, the last remnant of spermatid cytoplasm is rejected in
the form of a cytoplasmic droplet (CD). Human spermatozoa are
unique in that they do not develop a typical CD. The superfluous,
redundant cytoplasm (or ‘‘excess residual cytoplasm’’ [26]) in
human spermatozoa is an altogether different structure, as it may
not be rejected by the spermatozoon in a CD-like manner. It
coincides with increased content of reactive oxygen species (ROS)
in semen, which at high concentrations are cytotoxic [27]. The
ROS generated by excess sperm cytoplasm, or at least by some
types of it, can inflict damage by oxidation of unsaturated fatty
acids in the sperm plasma membrane, and by DNA breakage,
causing reduced motility, pregnancy loss, and embryo morbidity
[28].
We conducted the present study to determine the value of the
SPTRX3 as a predictor of ART treatment outcome, setting the
stage for the validation of SPTRX3 as a biomarker of human
male infertility. Our hypothesis was that infertile men will have a
significantly higher content of SPTRX3 present in their sperm
samples, compared to fertile males. We examined men from 239
couples undergoing infertility treatment because of previously
diagnosed female, male, combined (male and female) or
idiopathic infertility. We were particularly interested in assessing
possible effect of high semen SPTRX3 levels on pregnancy rates.
Results
High Flow Cytometric SPTRX3 Values Coincide with Low
Pregnancy Rates after ART
Sperm content of SPTRX3 was evaluated by flow cytometry
and correlated with pregnancy rates in 239 couples treated by
IVF and/or ICSI. The division of flow cytometric histograms
into markers M1-M3 (Figure 1) allowed us to distinguish
between cellular debris (M1), cells not carrying detectable
SPTRX3, with only a background-level of fluorescence (M2)
and SPTRX3-positive, defective spermatozoa (M3). The average
% of SPTRX3-positive cells (%M3) for the whole cohort of 239
couples was 14.3%. The average pregnancy rate for all 239
couples enrolled in this study was 25.1%. It was 29.8% for ICSI
treated couples (n = 131) and 19.4% for IVF couples (n = 108).
Average pregnancy rate for couples above the average %M3
level (n = 83) was 20.5%. Average pregnancy rate for couples
below the average %M3 (n = 156) was 27.6%. The median %M3
value, i.e. the value of %M3 at which half the subjects had
higher and half had lower SPTRX3 levels, was 12.01%. Average
pregnancy rate for couples above the median was 20.2%.
Average pregnancy rate for couples below the median was
30.3%, which was significantly higher than the average
pregnancy rates of the above-median group (p = 0.04).
The dosage effect of SPTRX3 on pregnancy rates was captured
when all 239 couples were divided into four groups based on
%M3-SPTRX3 values (less than 5% SPTRX3-positive spermato-
zoa; 5–9.99% positive spermatozoa, 10–14.99% positive sperma-
tozoa; 15% or more SPTRX3-positive spermatozoa). In this
partition, the percentage of pregnant couples decreased progres-
sively with the increased SPTRX3 values (Figure 2A). The
likelihood of pregnancy was further reduced if only the high
SPTRX3 men from idiopathic couples, were analyzed (Figure 2A;
last column). Average pregnancy rate of this group (n = 12) was
only 16.7%. Compared to men with less than 5% SPTRX3-
positive spermatozoa, those carrying more than 15% of such cells
had their chance of conceiving reduced by a half (41.2% pregnant,
vs. 19.2% pregnant; one-sided p,0.05). The ROC analysis
revealed that the cutoff values of 12.5% and 15% had a good
balance of test sensitivity and specificity (see Table S1 in File
S1). The average pregnancy rate in couples treated by ICSI and
having .15%% SPTRX3-positive spermatozoa (n = 60) was
36.7%. Average pregnancy rate was only 11.1% in IVF couples
with .15% positive spermatozoa (n = 18). The IVF couples with
,15% SPTRX3-positive spermatozoa (n = 90) achieved a preg-
nancy rate of 21.1%.
Discriminant analysis revealed that %M2 SPTRX3 was a
significant positive predictor of pregnancy in IVF couples and the
median M3 was a significant negative predictor for the ICSI
group (see Supplemental Statistics – Section ANALYSIS I
& Table S11 in File S1). Based on clinical indication,
SPTRX3 levels (%M3) were significantly higher (p,0.05) in
couples with male and combined (male and female) infertility,
compared to couples with female-only or idiopathic infertility
(Figure 2B). Also, SPTRX3 levels were significantly higher
(p,0.001) in ICSI couples compared to IVF couples
(Figure 2C). Within the ICSI-treated group, couples that
achieved pregnancy had numerically higher %SPTRX3 positive
spermatozoa, but this increase was not statistically significant.
The levels of sperm SPTRX3 were not significantly different
between smokers and non-smokers when all couples were
evaluated (Figure S2). Pregnancy outcomes were confirmed in
57/60 pregnant couples; 46 of those couples delivered babies
(confirmed live birth rate of 19.2%)(Table S2A in File S1).
High Semen SPTRX3 in Infertile Couples
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e61000
Lowest average SPTRX3 levels were found in couples that
delivered twins (n = 12; Figure 2E; Table S2B in File S1),
compared to those delivering a singleton (n = 34) and those that
miscarried (n = 10). In addition to pregnancy and live birth rates,
parameters of embryo development and numbers of oocytes and
embryos produced per couple were analyzed. Numerically,
couples in which men had less than 5% of SPTRX3 positive
spermatozoa produced most normal two-pronuclear zygotes and
transferable embryos (Table S3 in File S1). However, no
significant correlations were found between parameters of early
embryo development and flow cytometric SPTRX3 levels.
Flow Cytometric SPTRX3 Levels Reflect Clinicians’
Treatment Decision, and Reveal Undiagnosed Male
Infertility in Idiopathic Infertility Cases
The SPTRX3 levels in all 239 couples were compared based on
pregnancy outcome and clinical indication (Figure 2D). Com-
pared to female infertility couples, the average %M3 value of
SPTRX3 in diagnosed male infertility cases was increased by 63%.
Elevated SPTRX3 levels (.15% M3) coincided with the
clinician’s decision to treat by ICSI. Consequently, logistic
regression and discriminant function analysis were used to
determine the relationship between treatment assignment (ICSI
or IVF) and semen SPTRX3 levels (Table S4 in File S1;
Supplemental Statistics, section ANALYSIS II &
Table S12, S13 in File S1). Among 16 flow-cytometric
parameters, only median M2, Mean M2 and %M1 were not
significant for predicting the treatment assignment. Mean M1 and
Median M1 had the largest influence on the odds of being assigned
to IVF treatment. The odds of being assigned to IVF treatment
increased by over 34 fold and 4 fold for every unit of increase in
Mean M1 and Median M1, respectively. However, we noticed
that the ranges of Mean M1 and Median M1 were small (their
values varied between 1 and 4). The next three most influential
predictors were CV M1, %M2 and %M3. For every unit increase
in CV M1 and %M3, the odds of being assigned to FIV treatment
decreased by 16.3% and 9.6%, respectively. For every unit
increases in %M2, the odds increased by 14.1%. Discriminant
analysis identified %M2 SPTRX3 as a positive discriminant for
IVF assignment and Mean M3, Median M3 and % M3 SPTRX3
as positive discriminants for ICSI assignment. Thus, increased
SPTRX3 content in spermatozoa can be used as an indication for
ICSI treatment. Among the six conventional semen parameters,
only sperm volume was not significant predictor for treatment
assignment (Table S4 in File S1). Motility parameters, PR and
M gave the most explanatory powers with odds ratio of 1.176 and
1.142 (i.e. the odds of being assigned to IFV treatment increases
17.6% and 14.2% for every unit increase in PR and Mob
measurements, respectively).
Flow Cytometric SPTRX3 Values Reflect Sperm SPTRX3
Retention Phenotypes Observed by Epifluorescence
Microscopy
Immunofluorescence processing and subsequent analysis of a
subset of 150 samples by epifluorescence microscopy identified
varied phenotypes of SPTRX3- retention by defective spermato-
zoa, ranging from spermatozoa bearing a small dot of SPTRX3
(Figure 3A, 3E) to the highly SPTRX3-positive spermatozoa
(Figure 3D, 3G) and SPTRX3-containing cellular debris
(Figure 3F), readily obvious even at low magnification (compare
Figure 1. Examples of flow cytometric histograms (A, B) and corresponding light scatter diagrams (A’, B’) of two male patients with
varied SPTRX 3 levels. Histograms, representative of SPTRX3 fluorescene levels in 10,000 cells/sample are divided into marker areas M1 (low
fluorescent spermatozoa, sperm fragments and cellular debris), M2 (mostly intact spermatozoa with background-level fluorescence) and M3
(defective, SPTRX3-positive spermatozoa and immature sperm forms with high fluorescence). Percentage of SPTRX3-positive spermatozoa out of
total sperm content, including markers M1, M2, and M3 is shown. Gate R1 in scatter diagrams of visible light separates spermatozoa (each dot is one
cell) from other flow cytometric events; resultant percentage is percent of high/low fluorescent spermatozoa from total number of flow cytometric
events measured per sample in order to acquire 10,000 measurements. Sample B was donated by a patient previously diagnosed with male infertility
(oligo-astheno-teratozoospermia; 5 million sperm/ml, 30% motility, 22% normal morphology). Flat histogram-curve and a secondary peak within
marker area M3 coincide with 25.9% of SPTRX3–positive spermatozoa in this sample. Sample A was donated by a presumably fertile man with
acceptable clinical semen parameters (80 million/ml, 50% motility, 74% normal morphology) whose female partner suffered from endometriosis.
doi:10.1371/journal.pone.0061000.g001
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Figure 2. Diagrams of average SPTRX3 content in spermatozoa of men from 239 infertile couples. (A) Average pregnancy rates after
infertility treatment (IVF or ICSI) decreased gradually with the increased sperm SPTRX3-content in 239 couples divided by % of SPTRX3 spermatozoa
(flow cytometric %M3 value; x-axis) into subgroups with less than 5%, 5–9.99%, 10–14.99%, and more than 15% of SPTRX3-positive spermatozoa.
Compared to men with less than 5% SPTRX3-positive spermatozoa, those carrying more than 15% of such cells had their chance of conceiving
reduced by a half (41.2% pregnant, vs. 19.2% pregnant; one-sided p,0.05). (B) Low levels of sperm SPTRX3 were found in female and idiopathic
High Semen SPTRX3 in Infertile Couples
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Figure 3C to Figure 3B). Similar labeling was obtained in
spermatozoa immunolabeled without fixation (Figure 3H). Some
SPTRX3 positive spermatozoa persisted in semen samples
purified by gradient centrifugation and swim-up (Figure 3 I–K).
Non-sperm elements/bodies present in the analyzed samples did
not display detectable SPTRX3 fluorescence. The epifluorescence
microscopy-analysis of SPTRX3 correlated with flow cytometric
evaluation of this subset of 150 patients and was reflective of
pregnancy rates (Figure S3 in File S1; Table S5A, S5B in
File S1).
Effect of High SPTRX3 Content on Pregnancy Rates after
Adjustment for Partners’ Age
Female patients above 35 years of age tend to produce fewer
oocytes after superovulation, and these oocytes are perceived to be
of lesser quality and developmental potential. It was thus useful to
assess whether high semen content of SPTRX3 in male partners of
female patients 35 years or older could further aggravate couples’
infertility. When the couples were divided based on female age and
male content of SPTRX3 (Table S6 in File S1), and by age and
indication (Table S7 in File S1), there was a non-significant
trend towards higher pregnancy rates in low SPTRX3 couples
infertility-couples, compared to male I an combined male & female infertility-couples. Different superscripts mark statistically significant differences
between columns at p,0.001. The most significant difference was observed between female and male infertility couples (p,0.001). (C) Couples
treated by IVF had significantly lower average SPTRX3-levels than those treated by ICSI, regardless of whether or not they achieved a pregnancy.
Superscripts a, b mark statistical difference at p,0.05. The most significant difference was found between pregnant IVF couples and pregnant ICSI
couples (p,0.001). (D) Couples with female and idiopathic infertility had significantly lower SPTRX3 levels (average %M3-values) than couples
previously diagnosed with male or combined (male and female) infertility. (E) Distribution of SPTRX3 levels within cutoffs in patients divided based
on pregnancy outcome. Note that the couples delivering twins had the highest percentage of men with %M3 SPTRX below 15% and loweste
percentage of men with .15% M3 SPTRX3.
doi:10.1371/journal.pone.0061000.g002
Figure 3. Epifluorescence microscopy of sperm samples processed for flow cytometric measurements of SPTRX3 (red). The DNA-stain
DAPI (blue) was added after flow cytometric analysis. Epifluorescence images are superimposed onto parfocal differential interference contrast (DIC)
images (gray). (A) Examples of SPTRX3 labeling in samples from male infertility patients. Arrowheads point to minor carryovers of residual cytoplasm
in spermatozoa and immature sperm forms; some of these cytoplasmic structures may not be detectable by conventional transmitted light
microscopy, but can be identified accurately by SPTRX3 labeling. (B, C) The difference in SPTRX3 content is obvious even at low magnification
between a sample from a presumed fertile donor (B) and the one of a patient previously diagnosed with oligo-astheno-teratozoospermia (C). (D–G)
High magnification renderings of various patterns of SPTRX3 retention in defective spermatozoa, including a predominant sperm head/nuclear
labeling (D), minor SPTRX3 retention in the sperm head (E; arrows) and sperm tail connecting piece (E; arrowhead), sperm-derived cellular debris free
of DNA/chromatin (F), immature, spermatid-like form (G; top), and SPTRX3-filled large nuclear vacuole (G; bottom). (H) Immunolabeling of SPTRX3 in
a frozen-thawed semen sample labeled according to a simplified protocol omitting sperm fixation and washing. (I–K) Detection of SPTRX3 before (I)
and after semen purification on PureSperm gradient (J), and in a sample purified by swim-up after PureSperm treatment (K). Defective spermatozoa
are not removed completely by this two-step procedure. Scale bars are 10 mm in all panels except B, C, where they represent 20 mm.
doi:10.1371/journal.pone.0061000.g003
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regardless of female age. Male age itself did not show correlation
with pregnancy rates, SPTRX3 levels or conventional semen
parameters. There was a moderate-to-high correlation between
flow cytometric data and several parameters of conventional,
clinical semen analysis (Table S8 in File S1).
Next, the logistic regression analysis was applied to test the
relationship of pregnancy rate with the sperm quality parameters,
taking into consideration of female age and treatment assignments
(Supplemental Statistics – ANALYSIS III in File S1).
Considering only the patients assigned to IVF treatment, both
%M2 and %M3 SPTRX3 were significant predictors of
pregnancy rate, with or without adjustment for the female age
factor. Importantly, none of the conventional semen parameters,
or other remaining 14 flow cytometric SPTRX3 parameters, was
significant even with adjustment for the female age. The odds of
getting pregnant in the IVF group were significantly reduced by
increased %M3 value, with (p,0.05) or without (p,0.05)
adjustment for maternal age. The %M2 was also a significant
predictor for pregnancy rate for IVF group (p,0.02/p,0.05
with/without age adjustment).
For the ICSI group, the pregnancy rate was not affected by any
of the flow cytometric or conventional sperm quality parameters or
the female age factors. This is not surprising since ICSI can
overcome a wide range of sperm anomalies that would hinder
conventional IVF treatment. When considering all patients
together, %M2 and %M3 SPTRX3 were not significant
predictors for pregnancy rate (p.0.1). However, when we
categorized the %M3 levels into four groups (below 5%, between
5–10%, between 10–15%, above 15%), the estimated odds ratio
between the below 5% group and the above 15% group had a p-
value = 0.06. After adjusting for female age above/below 35 years,
the adjusted odds ratio for the ,5% SPTRX3 group over the
.15% SPTRX3 group had a p,0.05. Using 85% as a cutoff for
%M2 (normal spermatozoa), the below 85% group and above
85% group had significantly different pregnancy rates when
considering all patients together. The odds of getting pregnant for
the .85% %M2 group were significantly higher than that for the
,85% group (p,0.05) and the pregnancy rate was 41.6% versus
22.72%. After the adjustment for the female age above 35, the
odds ratio remained significant (p,0.05).
Relationship between Flow Cytometric SPTRX3
Parameters, Clinical Semen Parameters and Clinical
Diagnosis of Male Infertility
This analysis was performed using logistic regression analysis
(SAS proc log) of SPTRX3 parameters and conventional semen
parameters including sperm concentration (C), semen volume (V),
% normal spermatozoa (NX), progressive motility (PR), % motile
(M) and % necrotic (NEC)(Table 1). All parameters except V
were significant predictors for the clinical diagnosis of male
infertility (Table 2). NX, PR, M and C were negative predictors
for male infertility. Among 16 flow cytometric parameters
(Table 2), Mean M1, Median M1, CV M1, %M2 and %M3
were the most sensitive predictors for male infertility. Discriminant
function analysis identified PR, M, NX, C, %Total and %M2
SPTRX3 as the discriminants correlated positively with sperm
quality (Supplemental Statistics – Section ANALYSIS IV,
Table S14, S15 in File S1). Negative discriminants included
%M3, Mean M3 and Median M3 SPTRX3. Analysis based on
etiology/testiculopathy (Table 3) revealed highest levels of
SPTRX3 in men from male infertility couples (n = 72) diagnosed
with oligo-asthenozoospermia. Couples with astheno-teratosper-
mia had the lowest SPTRX3 and highest pregnancy rates.
Altogether, 97.2% of male-only infertility couples were treated
by ICSI. Spearman rank correlation was used to confirm the
relationship between sperm SPTRX3 values and conventional
semen parameters. Five most informative flow cytometric
SPTRX3 parameters (Mean M1, Median M1, CV M1, %M2,
%M3) were significantly correlated with conventional semen
parameters, particularly with motility parameters M and PR
(Table S9 in File S1). The %M3 parameter, capturing cells with
high SPTRX3 content, also correlated negatively with % normal
spermatozoa (NX) and sperm count (C), and positively with %
necrotic spermatozoa (NEC).
Discussion
Present statistical analyses indicate that high semen content of
SPTRX3 in infertile men translates into a reduced chance of
impregnating their female partners via ART. In fact, couples’
pregnancy rates were significantly lower for men with .15%
SPTRX3 sperm compared to men with ,5% SPTRX3 cells.
Since the treatment decision/assignment in the examined 239
cases was in part based on semen analysis, it is no surprise that
men from IVF couples had significantly lower average SPTRX3
levels than men from couples that were treated by ICSI. That the
increased levels of SPTRX3-positive spermatozoa predispose
couples for ICSI treatment is obvious in spite of the fact that
several couples were initially treated by IVF, without success,
before the ICSI treatment was applied. Altogether, pregnancy
rates fell progressively with increasing semen SPTRX3 levels.
When broken down into ICSI and IVF groups, couples divided
by %M3 SPTRX3 showed high pregnancy rates in ICSI group
with ,5 %M3. On average, ICSI and male infertility cases had
significantly higher %M3 values but also slightly higher pregnancy
rates than IVF and female-only infertility cases. This is under-
standable because most of these cases were oligo-astheno-
teratozoospermic and therefore treated by ICSI. The IVF patients
had overwhelmingly female-only infertility, with poor oocyte
quality being the likely contributor to a high incidence of failed
IVF treatment (75%). However, this could also have been
compounded by undiagnosed male infertility, indicated by high
SPTRX3 levels in 20% of those presumed female-only infertility
couples. Consequently, the percentage of mature oocytes that
formed two pronuclei after assisted fertilization decreased in a
stepwise manner, in parallel with increasing %M3 SPTRX3 in
both the IVF-treated and ICSI-treated couples. Altogether, high
sperm SPTRX3 levels seem to coincide with clinical decision to
treat by ICSI. The SPTRX3-levels corroborate previous clinical
diagnosis of male infertility, and reveal undiagnosed male
infertility in a fraction of cases with idiopathic and female-only
infertility.
While the majority of the 239 couples in this study were
assigned to IVF or ICSI based on their clinical test results, our
SPTRX3 results indicate that approximately 20% of IVF couples
would have profited from ICSI because of undiagnosed male
infertility. Table S3 in File S1 shows that sperm SPTRX3-levels
but not couples’ clinical diagnosis, in part based on subjective
semen analysis, coincided with successful fertilization and forma-
tion of two normal pronuclei in the resultant zygotes. While
couples with ,5 %M3 values of SPTRX3 produced 2-PN zygotes
in 86.2% of fertilized oocytes, idiopathic couples with .15 %M3
did so in only 69.7% of oocytes (see Table S3A in File S1;
column 9). No such differences were observed based on clinical
diagnosis/indication (Table S3B in File S1). There was no
significant difference in %M3 values of SPTRX3 between female
and idiopathic cases. However, 20% of the idiopathic cases
showed high SPTRX3 values (.15% M3), indicating that these
High Semen SPTRX3 in Infertile Couples
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were in fact male infertility cases. Similarly, 20% of presumed
fertile males in couples diagnosed with female-only infertility also
had .15% SPTRX3-positive spermatozoa. Together with the
effect of SPTRX3 on pregnancy rates, these data illustrate the
predictive value of SPTRX3-based semen analysis for treatment
outcome.
Table 2 and Table S8 in File S1 reveal relationship between
clinically diagnosed male infertility and SPTRX3 parameters.
Furthermore, Table 1 shows that men with high SPTRX3 levels
show acceptable clinical semen parameters, but low pregnancy
rates are achieved by their female partners. As shown in Table S8
in File S1, the levels of correlation (r-values) between flow
cytometric parameters (%M3; %TOTAL, GeoMean M3) and
conventional semen parameters are varied, depending on how the
patient pool was subdivided based on indication, treatment
decision and treatment outcome. All three flow cytometric
parameters show median level of correlation with some clinical
semen parameters in some subgroup but not in others. This
indicates that sperm SPTRX3 values are relatively independent of
conventional semen parameters. The flow cytometric parameter
most closely correlated with clinical semen parameters is the
%TOTAL, which reflects the percentage of flow cytometer-
registered events corresponding to intact spermatozoa (both
morphologically normal and abnormal) out of all objects passing
through a flow cytometer, including sperm fragments and debris
present in semen sample. This is based on visible light scatter of
registered events rather than on SPTRX3-induced fluorescence.
The proposition of a sperm quality test that is relatively
independent of conventional semen parameters but predictive of
pregnancy outcome arrives at a time of renewed calls for more
accurate semen analysis. Some recent studies even go as far as
implying that even the strictest, most accurate morphological
criteria could lead to diagnosis of teratozoospermia that forces
unnecessary ICSI treatment in couples treatable by IVF [29].
No single biomarker is a universal indicator of male infertility
and treatment outcome; however, the SPTRX3-based assay could
be combined with other immunocytochemical and cytochemical
tests such as the ubiquitin-based sperm quality assay [16] or a test
of sperm acrosomal status based on lectin labeling [7]. SPTRX3 is
a unique marker because it is a well characterized, germline-
specific protein with a distinct localization pattern in spermatozoa,
and there is no need to measure its relative abundance in
individual cells to decide which cells are ‘‘positive’’ and which are
‘‘negative.’’ Most normal spermatozoa do not contain amounts of
SPTRX3 detectable by immunofluorescence. Simply counting
positive and negative spermatozoa is straight-forward and, if
desired, such a test gives numbers that could be used to set up clear
cutoffs for normal and infertile males. However, thresholds will be
different for manual, epifluorescence microscopy based assess-
ments as opposed to automated flow cytometric measurement.
Discriminant function analysis of flow cytometric data and clinical
diagnosis showed that the mean % of SPTRX3-postitive
spermatozoa (%M3) was for 11.6% in presumed fertile men vs.
18.6% in the clinically diagnosed infertile men (Supplemental
Statistics – ANALYSIS IV in File S1). The cutoff values of 12.5
and 15% were found to have a good balance of sensitivity and
specificity in ROC analysis (Table S1 in File S1). A 10% cutoff
value had sensitivity close to 90%, but this was at the expense of
specificity. The threshold/cutoff levels for an infertile male could
also differ between IVF patients (e.g. 7.5 or 10% positive) and
ICSI patients (e.g.15 or 17.5%). Thus, SPTRX3-based test could
be used as a decision making tool when physicians have to decide
whether to use intrauterine insemination, IVF, or ICSI. For
example, a treatment with intrauterine insemination could be used
in cases when a male partner’s SPTRX3 levels are below 10%
positive spermatozoa, IVF for men with between 10–15%
SPTRX3 positive spermatozoa, and ICSI for men with .15%
positive spermatozoa.
Similar to flow cytometric SPTRX3 analysis, the simplified,
light microscopic analysis revealed higher pregnancy rates in
couples with low SPTRX3 levels (Table S6 in File S1). While
the more sensitive flow cytometric analysis would be preferable,
the simplified light microscopic test could become a valuable tool
for clinical semen evaluation wherever flow cytometry is not
convenient or available. This could be done either by epifluores-
cence microscopy (direct conjugation of a fluorescent probe to
anti-SPTRX3 antibody), or by simple transmitted light microsco-
py using anti-SPTRX3 antibody conjugated to horse radish
peroxidase and developed by applying alkaline phosphatase or
DAB. To further facilitate sample staining, sperm spreads would
be fixed by methanol and dried directly on the microscopy slides.
Even so, development of simplified protocols for flow cytometric
semen analysis is necessary. As shown in Fig. 3 H, spermatozoa
can be labeled with antibodies without previous fixation, i.e. by a
Table 2. Relationship between the clinically diagnosed male
infertility and individual, conventional and flow cytometric
SPTRX3 parameters reflective of sperm quality.
Parameter p-value Odds ratio*
V 0.9833 NA
PR ,0.0001 0.677
NX ,0.0001 0.903
NEC ,0.0001 1.07
M ,0.0001 0.772
C ,0.0001 0.948
Median ALL 0.0007 1.055
Median M3 ,0.0001 1.028
Median M2 0.0176 1.074
Median M1 ,0.0001 0.08
Mean all ,0.0001 1.055
Mean M3 ,0.0001 1.022
Mean M2 0.0249 1.084
Mean M1 ,0.0001 0.014
Total ,0.0001 0.915
%M3 ,0.0001 1.12
%M2 ,0.0001 0.869
%M1 0.8212 NA
CVALL 0.0005 1.007
CVM3 0.0131 1.012
CVM2 0.3455 NA
CVM1 ,0.0001 1.241
An odds ratio smaller than 1 indicates that the parameter is negatively
associated with the odds of being diagnosed with male infertility. A larger than
1 odds ratio indicates a positive relationship between the parameter and the
clinical diagnosis of male infertility. An odds ratio larger than 1, e.g. 1.12 is
interpreted as ‘‘the odds of being diagnosed with male infertility increase by
12% for every unit of increase in the parameter measurements.’’ An odds ratio
smaller than 1, e.g., 0.014, is interpreted as ‘‘the odds of being diagnosed with
male infertility decrease by 98.6% for every unit of increase in the measured
parameter.’’ Abbreviations: C = sperm count; V = semen volume; M= total
motility; PR = progressive motility; NX =morphology/% normal spermatozoa;
NEC= percent of necrotic spermatozoa assessed by Williams test.
doi:10.1371/journal.pone.0061000.t002
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mild permebilization and immunolabeling. Permebilization kills
spermatozoa but in this case, it cannot be omitted because the
SPTRX3 antigen is concealed under the plasma membrane of the
membrane-intact spermatozoa. This protocol will address the
major disadvantage of SPTRX3 test compared to other flow
cytometry based sperm test such as SCSI or TUNEL, i.e. the
lengthy, multi-step processing. This approach would benefit the
new generation of dedicated sperm analysis flow cytometers such
as Easy Cyte Plus, a capillary flow-based device with pre-set sperm
tests, used to analyze small volumes of sperm suspensions [30].
The SPTRX3 based test may be a valuable addition to the
aforementioned flow cytometric tests. Out of five male infertility
patients tested by SCSI in the present cohort, none had the DNA
fragmentation index (DFI) above the threshold level of 20% (Mean
DFI = 7.862.2%; range 2–14%). However, the average %M3
SPTRX3 for these five patients was 25.167.0% (range 7.8-
50.0%), compared to 18.761.2 %M3 of the entire cohort of male
infertility patients. Future trials will be designed to examine the
relationship between SPTRX3 retention and aberrant sperm
chromatin structure.
The SPTRX3-positive spermatozoa most likely correspond to
spermatozoa commonly referred to as ‘‘immature sperm’’ [31].
Superfluous cytoplasm can be very conspicuous in some of these
spermatozoa, but difficult to detect by conventional light
microscopy in others, even with high magnification lenses and
DIC contrast optics. The use of SPTRX3 as a biomarker could
allow clinicians to identify defective spermatozoa during semen
analysis that would be undetectable to conventional semen
evaluation. The SPTRX3 based method is robust, and as
demonstrated here, capable of detecting sperm defects in men
from couples diagnosed with idiopathic infertility. Altogether, the
present study documents the relationship between SPTRX3 levels
and pregnancy rates after ART, and the effect of SPTRX3 on
quality of zygotes (number of pronuclei); it also identified
differences in semen content of SPTRX3 and phenotypes of its
retention between male patients from couples treated by ICSI and
those treated by conventional IVF. Consequently, it may be
possible, and necessary to set the threshold levels for normal/
elevated semen SPTRX3 content differently for these two cohorts
of infertility patients. Altogether, SPTRX3 protein is a candidate
biomarker of sperm dysfunction that is relatively independent of
clinical semen parameters, and relevant to decision making in
ART.
Materials and Methods
Semen Samples and Study Design
Semen samples were donated by men from 239 consenting
couples, free of HIV and any other detectable contagious diseases,
presenting for infertility treatment at the Assisted Fertilization
Medical Center, Clinique Monplaisir, Lyon, France. Semen was
collected on the day of IVF/ICSI and the leftover was sample
cryopreserved within two after collection hours. Identities of
donors were not disclosed to researchers involved in this study. All
couples also consented to sharing of diagnostic data and treatment
outcome-data. Couples were classified and assigned as follows:
Female infertility included hydrosalpinx, endometriosis and
polycystic ovary syndrome (PCOS); these couples were assigned
to IVF since their sperm parameters were within acceptable limits
by WHO criteria. This group also included ovarian insufficiency
revealed by ultrasonographic baseline antral follicle count,
associated with other pathologies; such cases were treated by
ICSI. Male and combined male and female infertility was
diagnosed based on semen analysis, as described below. Clinical
indications of male infertility, as defined by WHO, included
asthenozoospermia (A), astheno-teratozoospermia (AT), oligo-
asthenozoospermia (OA) and oligo-astheno-teratozoospermia
(OAT). Cases of obstructive azoospermia (AZ), obstructive
OAT, teratozoospermia, obstructive OT, azoospermia due to
vasectomy, varicocele, and anti-sperm antibodies were present. In
vasectomy cases and cases of obstructive OAT due to inflamma-
tion, spermatozoa for ICSI were collected from testis. Five male
infertility patients were tested for chromatin structure/DNA
fragmentation by SCSI at a commercial laboratory, but all five
had acceptable DNA-fragmentation index (,20% DFI). Gener-
ally, IVF was used in cases with acceptable progressive motility,
while cases of OAT were treated by ICSI. Idiopathic infertility (no
clinical symptoms or pathologies, and no previous history of
andrological problems in male partners) were treated by ICSI if
they reported previous failures with intrauterine insemination
(IUI). If there was no history of IUI, couples were assigned to IVF
Table 3. SPTRX3 levels and ART outcomes in 72 male infertility patients divided by etiology.
Aethiology A AT OA OAT AZ* Other** AVG/Total
Mean %M3 SPTRX3 18.4 14.8 28.2 18.4 25.6 17.6 18.7
SE 2.6 2.5 7.2 1.6 8.4 3.9 1.2
N 14 9 4 33 3 9 72
Pregnant/total (%) 2/14 (14%) 4/9 (44%) 0/4 (0%) 12/33 (36%) 3/3 (100%) 2/9 (22%) 23/72 (32%)
ICSI-treated/total (%) 12/14 (86%) 9/9 *** (100%) 4/4 (100%) 33/33 (100%) 3/3 (100%) 9/9 (100%) 70/72 (97%)
Most frequent etiologies included asthenozoospermia (A), astheno-teratozoospermia (AT), oligo-asthenozoospermia (OA), and oligo-astheno-teratozoospermia (OAT).
One patient had obstructive azoospermia and one had obstructive oligo-teratozoospermia. Other, less frequent etiologies included teratozoospermia (2 patients),
obstructive (1), vasectomy (1), varicocele (1), anti-sperm antibodies (2) and asthenozoospermia with anti-sperm antibodies (1). One couple reported failed IVF before
being treated by ICSI. Couples diagnosed with combined male & female, female-only or idiopathic infertility excluded from this analysis/table.
A = asthenozoospermia.
AT = astheno-teratozoospermia.
OA=oligo-asthenozoospermia.
OAT= oligo-astheno-teratozoospermia.
*Obstructive.
**Other = teratozoospermia (2 patients), oligo-teratozoospermia, obstructive (1), vasectomy (1), varicocele (1), anti-sperm antibodies (2), asthenozoospermia with anti-
sperm antibodies (1).
***One couple reported failed IVF before being treated by ICSI.
doi:10.1371/journal.pone.0061000.t003
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treatment. In several cases, couples were assigned to ICSI
treatment because of reported IVF failure.
Male infertility was diagnosed by applying conventional WHO
cutoff values valid at the time of sample collection (2002–2003) for
sperm count (C), semen volume (V), total motility (M), progressive
motility (PR). Percentage of spermatozoa with normal morphology
(NX; % normal spermatozoa) was established by using David’s
classification [32,33], which was the most common method for
sperm morphology assessment at the time of treatment in France,
where all samples and clinical parameters for this study were
collected. Volume was measured with a calibrated 15 ml Falcon
tube. Spermatozoa were counted using a Thoma Chamber at a
lens magnification of 10 or 206; spermatozoa were immobilized
using 36% formaldehyde and stained with methylene blue. Sperm
morphology was assessed by Harris and Shorr staining. Percent of
necrotic spermatozoa (NEC) was assessed by Williams test (eosin
staining). Clinical data were provided to researcher after the
completion of flow cytometric data collection. Couples that had
ICSI following a failed IVF treatment are included in the ICSI-
group for the purpose of analysis. Conventional semen evaluations
and cryopreservation were performed at Clinique Monplaisir,
Lyon, France. Analyzed samples were cryopreserved in sperm
freezing medium (Medicult Origio), in which they were diluted
progressively to 1:1 v/v ratio during a ten-minute incubation at
20uC. Slow cooling from 20uC to 240uC at 2uC/minute was
followed by plunging in liquid nitrogen. Cryopreserved sperm
samples were processed and analyzed by flow cytometry and
epifluorescence microscopy at the University of Missouri, under an
approved Internal Review Board (IRB) protocol.
All 239 samples were analyzed by flow cytometry. A randomly
chosen subset of 150 samples was examined by epifluorescence
microscopy to assess the percentage of SPTRX-3 positive cells
(100 spermatozoa examined randomly per slide), and the data
were correlated with the flow cytometric data. Both SPTRX3
assays were done on semen samples left over from ART treatment.
Western blotting trials (Figure S1 in File S1) were conducted on
three samples from the patients diagnosed with extreme male
infertility (dysplasia of the fibrous sheath) and on three samples
from presumed fertile donors, purchased from the Fairfax
Cryobank, Fairfax, VA. These trials were designed to confirm
the specificity of the SPTRX3 antibody used for flow cytometry,
and to explore a possibility of SPTRX3 quantification based on
densitometry technique.
ART Treatment, and Evaluation of Embryos and
Pregnancy Rates
Spermatozoa for both IVF and ICSI were purified on a 90%/
70% PureSperm density gradient by centrifugation at 2506g,
diluted and washed at 1,3506g with IVF medium (Medicult,
Origio France, Limonest, FR). Sperm pellets were resuspended in
300 ml of IVF medium for IVF or in 100 ml for ICSI. Spermatozoa
were incubated for 1 hour at 37uC and 5.5% CO2 before ART
treatment. Fertilization was performed with 100,000 spermatozoa
(125,000/ml) and a maximum of 4 oocytes. In vitro fertilization was
performed in IVF Medium (MediCult, Origio France) supple-
mented with sodium pyruvate and synthetic medium replacement
(SSR; Origio France). A female patient was considered pregnant if
her hCG was above 1000 UI and a gestational sac was detected by
ultrasonography. Spermatozoa for ICSI were immobilized in
clinical grade PVP medium with HEPES, sodium pyruvate and
SSR. Individual spermatozoa for ICSI were selected at a 1,000x
magnification based on morphology (David’s classification;
[32,33]). In several teratospermic patients (severe oligo-astheno-
teratozoospermia), it was impossible to find morphologically
normal spermatozoa. The embryos were cultured in Global
medium (LifeGlobal; lifeglobal.com). Embryos were evaluated on
day 2, 48 hrs post oocyte pick-up, applying the following criteria of
normal morphology: Minimum of 4 cells and maximum of 6 on
day 2, with regular blastomere size and homogeneous cytoplasm,
with ,10 % of exudate (cytoplasmic fragments). Only embryos
that met the above criteria were used for cryopreservation.
Embryos were cultured in vitro for up to 6 days (blastocyst stage).
The embryos which were not transferred or cryo-preserved on day
2 were re-evaluated on day 6, but the results of the second
cryopreservation were not included in this study.
Sperm Processing for Flow Cytometry
The sperm samples were stored and shipped in individual straws
in liquid nitrogen, and processed by a method modified from
sperm ubiquitin assays described previously [34]. Five microliters
of Tyrode-Lactate-HEPES medium (TLH) were added per tube to
15 ml Falcon polypropylene centrifuge tubes (Becton Dickinson,
Franklin Lakes, NJ), and the thawed contents of each straw were
added to the correctly labeled tubes. The use of similar size
polystyrene tubes was avoided deliberately as we found previously
that many spermatozoa adhere to their walls and are lost during
centrifugation. The mixture was spun for 5 minutes at 3506g in a
bench-top, fixed angle rotor centrifuge (Centrific; Fischer Scien-
tific) and the supernatant was removed by a Pasteur pipette
attached via flexible tube to an air pump, making sure to not
disturb the sperm pellet at the bottom of the tube. Next, 5 ml of
2% formaldehyde (EM grade; Polyscience, Warrington, PA) in
phosphate buffered saline (PBS) were added to each tube and
vortexed. The samples were fixed for 40 min at room temperature
(RT) and washed by centrifugation in 8 ml of PBS. After complete
removal of the washing buffer, 80 ml of PBS were added per tube.
To permeabilize the cells and block potential non-specific
antibody binding, 10 ml of 20 % normal goat serum (NGS;
Sigma) in PBS with 1 % Triton-100 (Sigma) were added to each
tube. After one hour of incubation at room temperature, 10 ml of
affinity purified, peptide-specific anti-SPTRX3 antibody [14],
diluted1:30 in PBS with 1% NGS and 0.1% TX-100, were added
to each tube. The specificity and quantitative nature of this
antibody is demonstrated by Western blotting of semen samples
from three presumed fertile donors and three patients diagnosed
with heritable male infertility (Figure S1 in File S1; Table S10
in File S1). The samples were incubated overnight at 4uC. The
next day, 10 ml of goat-anti rabbit IgG conjugated to a red
fluorescent dye TRITC (GAR-TRITC; Invitrogen-Zymed; Carls-
bad, CA), diluted 1:9 in PBS with 1% NGS and 0.1% TX-100,
were added to each tube. Samples were incubated for 40 min at
RT, and washed with 5 ml of PBS-BSA. The washed sperm pellets
were resuspended in 500 ml of pure PBS and transferred into 5 ml
Falcon flow cytometry tubes (Becton Dickinson, Franklin Lakes,
NJ) with cell strainer caps, to remove large debris and agglutinated
cells. A shortened version of this protocol was tested on several
samples in which fixation and blocking were omitted and the
frozen-thawed samples were incubated for 20 min with anti-
SPTRX3 antibody diluted in PBS with 1%NGS and 0.1% TX-
100. After 20 min, the concentrated GAR-TRITC was added and
the samples were viewed under epifluorescence microscope after
additional 20 min. of incubation (representative results shown in
Figure 3H). None of these samples were included in the flow
cytometric analysis.
Flow Cytometric Analysis
Flow cytometry was performed using FacsScan flow cytometer
(Becton Dickinson Corp.), measuring 10,000 cells per sample at
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568 nm light wavelength. Acquired relative intensities of TRITC
labeling were plotted as histograms and divided into three areas of
low (marker area M1), medium (marker area M2) and high relative
intensity (marker area M3; see Figure 1A, 1B), essentially as
described for ubiquitin, PAFR and 15-LOX proteins in animal
spermatozoa [35,36]. The marker area M1 contains the low-
fluorescent sperm fragments and debris. Marker area M2 delimits
background fluorescence of intact spermatozoa not carrying
SPTRX3, with some content of larger debris particles. Marker
area M3 contains the spermatozoa, large sperm-derived debris
and immature sperm forms with accumulated, fluorescently
labeled SPTRX3 protein (SPTRX3-positive spermatozoa). Blank
negative control samples generated by the replacement of anti-
SPTRX3 antibody with a non-immune rabbit serum were
evaluated in the same trial under identical conditions. For each
sample, the following flow cytometric parameters were recorded
and entered in MS-Excel tables: Percentage of total cell numbers
within marker areas M1-M3 (%M1, %M2, %M3), median
fluorescence of all cells in a sample and of the cell subpopulations
within marker areas M1-M3 (SPTRX3 Median All, M1, M2, M3),
geometric mean of relative fluorescence of all cells in sample
(GeoMean), mean relative fluorescence of all cells (Mean All,
Mean M1-M3) and cells in M1-M3, coefficient of variation (CV;
normalized standard deviation CV = SD/Mean), and Peak
Channel. Additionally, the % of flow cytometric events registered
in visible light scatter as cells of prevailing size out of all events
within the whole measured sample were recorded as the % Total
values, reflective of relative ratio of combined high and low
fluorescence spermatozoa to low-fluorescent small debris in a
sperm sample (see Figure 1A’, 1B’).
Statistical Analysis
Regression analyses were conducted in SAS using proc glm
procedures to investigate the relationship between the SPTRX3
levels and the clinical indication and treatment variables. Logistics
regression analysis was conducted using proc logistics to investigate
the relationship between the pregnancy rate and the SPTRX3
levels, female age variables and treatment assignment. SAS proc corr
procedure was used to perform a Spearman rank correlation study
of relationship between conventional and flow cytometric semen
parameters. Discriminant analysis was performed using SAS proc
discrim and proc stepdisc procedures. Cutoff values for diagnosis of
male infertility based on %M3 value were established by Receiver
Operator Characteristic (ROC) curve analysis. Descriptive statis-
tics and Pearson’s correlation coefficients were generated by using
statistical tools package in MS-Excel. Values of %M3 and
GeoMean were found to be most informative and are listed in
the Tables. The value of % TOTAL also showed a strong
correlation with some of the clinical semen parameters.
Analysis by Epifluorescence Microscopy
A randomly chosen subset of 150 samples were examined under
a Nikon Eclipse 800 epifluorescence-equipped light microscope to
determine the percentage of SPTRX3-positive cells, by using the
processed, but unexposed sample remnants left over from flow
cytometric measurements. Following the flow cytometric analysis,
each leftover sample was transferred from a 5 ml flow cytometry
tube to a 1.5 ml Eppendorf tube, sealed and stored at 4uC until
mounting and analysis. Filtered PBS was added up to approx-
imately the 0.5 ml mark and 2.5 ml of DNA dye DAPI (200 mg/ml
stock) were added to each tube. The samples were spun for
1 minute at 5006g in Sorvall Biofuge Fresco centrifuge to
concentrate the sperm in a pellet, of which 7.5 ml were mounted
on a clean slide. Slides were covered by coverslips, sealed with
clear nail polish and stored at 4uC until evaluation. At least 100
spermatozoa were counted per slide and were categorized into two
different groups, SPTRX3-positive cells and SPTRX3-non
positive cells. Positive cells were further divided by the association
of SPTRX3 labeling with the sperm head or sperm tail. The sperm
head category had SPTRX3 in the nuclear vacuoles while the
sperm tail category included labeling in the redundant cytoplasm
around the proximal midpiece as well as the association of
SPTRX3 extending from the sperm tail connecting piece toward
the post-acrosomal sheath of the sperm head. The percentages of
all SPTRX3-positive spermatozoa and the percentages of head/
tail-positive spermatozoa were entered in MS-Excel tables and
correlated with flow cytometric data. Representative images were
acquired by a CoolSnap HQ CCD camera operated by
MetaMorph software, using appropriate epifluorescence filters
on a Nikon Eclipse E800 microscope. Images were edited using
AdobeH Photoshop CS5 Extended version (Adobe Systems, Inc.,
San Jose, CA, USA).
Supporting Information
File S1 Supplemental figures and tables. Figure S1.
Western blotting of SPTRX3 in semen of three ART patients
and three presumed fertile donors (semen parameters are shown in
Table S10). Relative levels of SPTRX3 (top panel) and beta-
tubulin (loading control; middle panel) are shown for three
presumably fertile sperm bank donors with acceptable clinical
semen parameters (lanes 1-3) and three teratozoospermic infertile
men (lanes 4-6) suffering from dysplasia of the fibrous sheath.
Diagram of SPTRX3/tubulin band density ratios is shown on the
bottom. Note the high density of SPTRX3 band in donor#1, who
was presumed fertile. Figure S2. Smoking has a modest effect on
sperm SPTRX3 levels. Heavy smokers consuming 15-30 cigarettes
per day had higher average levels of sperm SPTRX3 than other
groups shown. Of note, two thirds (10/15) of these heavy smokers
had indication/clinical diagnosis of male infertility. The numeric
difference between smokers consuming 2-5 cigarettes per day and
smokers consuming 15-30 cigarettes per day, was not statistically
significant (p.0.1). Figure S3. Scatter diagram illustrating the
relationship between subjective, light microscopic assessment of
sperm SPTRX3 content (% spermatozoa with SPTRX3-positive
heads; x-axis) and flow cytometry (%M3 SPTRX-value; y-axis).
This simple light microscopic analysis was conducted as a potential
precursor of a test suitable for clinical andrology laboratories.
Samples from 150 randomly chosen donors, processed for flow
cytometry, were re-evaluated by epifluorescence microscopy for
the percentage of SPTRX3 positive sperm heads, sperm tails, and
total % of SPTRX3 positive spermatozoa. Correlations were
found between all three categories of light microscopic evaluation
and % of SPTRX3-positive spermatozoa as measured by flow
cytometry (%M3). The highest correlation coefficient (r = 0.46)
was between % SPTRX3-positive sperm heads by light micros-
copy and %M3 SPTRX3 by flow cytometry (see Table S4B).
Table S1. Receiver Operator Characteristic (ROC) analysis. As
anticipated, Specificity increases at the expense of Sensitivity as the
cutoff values increase. The area under the ROC curve is 0.74,
which shows that the %M3 performs well for predicting the male
infertility. Table S2. Semen SPTRX3 levels and live births.
Pregnancy outcomes were available for 57/60 pregnant couples.
One of those 57 pregnancies was an ectopic pregnancy in a case of
female-only infertility; it is not included in the above table. Live
birth was achieved in 81% (46/57) of those analyzed pregnant
couples. One of those three male factor patients had a vasectomy.
Table S3. Parameters of zygotic development in 239 couples
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divided into subgroups based on percentages of SPTRX3-positive
spermatozoa (A) or clinical indication (B). SPTRX3 values, but not
the clinical indication, were predictive of good zygotic develop-
ment after IVF or ICSI. Couples with lowest SPTRX3 levels (A,
top row, ,5% M3) produced the highest percentage of normal,
two-pronuclear (2 PN) zygotes out of all fertilized oocytes (A,
column 8), and also when calculated based on all oocytes
harvested (A, column 9). These couples also produced the most
embryos suitable for transfer or cryopreservation (column 13).
Note that couples with low or medium levels of SPTRX3
produced more 2PN zygotes per couple on average than couples
with .15% SPTRX3 (A, column 10). Idiopathic couples in which
men recorded more than 15% SPTRX3-positive spermatozoa had
the lowest yields of two-pronuclear zygotes. Numbers shown in red
are highest & lowest values for each column. No significant
correlations were found between parameters of early embryo
development and flow cytometric SPTRX3 levels. Table S4.
Relationship between the clinical treatment assignment and
various sperm quality parameters. Table S5. A: Pregnancy rates
in 150 infertile couples, divided by percentages of SPTRX3-
positive spermatozoa. In accordance with flow cytometric
SPTRX3-data, couples with lowest levels of SPTRX3 had highest
pregnancy rate (column 2). Also similar to flow cytometric results,
the percentage of couples treated by ICSI increased progressively
with sperm SPTRX3 content (column 6). Spermatozoa were
evaluated for the presence of SPTRX3 in the sperm head (B) or
tail (C; combined head and tail labeling has not been observed),
adding up to third category of total SPTRX3-positive spermatozoa
(A). Numbers shown in red are highest & lowest values for each
column. With the exception of one SPTRX3 parameter (A-% of
all positive spermatozoa), pregnancy rates (column #2) in light
microscopic analysis were dose-dependent on SPTRX3 values. B:
Correlations between light microscopic SPTRX3-evaluation
(STIX assay) and % of SPTRX3-positive spermatozoa as
measured by flow cytometry. Bold font indicates highest
correlation coefficients for flow cytometric and light microscopic
parameters. Table S6. Sperm SPTRX3 levels and oocyte quality
parameters in 238 couples divided by female partners’ age, with
the threshold of 35 years of age. Female age subgroups (in rows)
were further divided based on male partners’ semen content of
SPTRX3-positive spermatozoa (Column 4), and based on the
treatment (IVF or ICSI, columns 6 & 7). Regardless of female
partner’s age, the combined IVF & ICSI pregnancy rates (column
9) as well as the ICSI pregnancy rates (column 10) were
numerically higher when the male partner had ,10%
SPTRX3-positive spermatozoa. Table S7. Analysis of subgroups
divided by indication (male or female infertility) and female age.
Combined and idiopathic cases were not included in analysis.
Table S8. Correlations between flow cytometric SPTRX3 values
and clinical semen parameters. R-values by Person’s correlation
analysis are shown. Most significant values are printed bold. In
general, SPTRX3 values correlate negatively with sperm count,
motility, and percentage of morphologically normal spermatozoa
in samples, assessed by conventional light microscopic semen
evaluation. Ratio of spermatozoa to debris (%TOTAL) correlates
positively with sperm count, motility and normal morphology.
Bold font indicates highest correlation coefficients. Table S9.
Spearman correlations between the most informative flow
cytometric SPTRX3 parameters and the conventional semen
parameters (the second numbers in the cells are the p-values).
Table S10. Conventional semen parameters for semen samples
used for Western blotting. Table S11. Discriminant analysis using
SAS PROC discrim and stepdisc procedures applied to study the
relationship of pregnancy rate with the sperm quality parameters
and SPTRX3 levels, with consideration of treatment assignments.
Table S12. Structure matrix of the discriminant analysis
conducted to study the relationship of the treatment assignment,
SPTRX3 and the sperm quality parameters. Table S13. Variables
and treatment groups in the discriminant analysis conducted to
study the relationship of the treatment assignment, SPTRX3 and
the sperm quality parameters. Table S14. Canonical structure
matrix of the discriminant analysis using SAS proc discrim
procedure, conducted to explore the relationships between the
clinically diagnosed male infertility and sperm quality parameters.
Table S15. Means of the nine variables shown separately for
infertile and fertile male in the discriminant analysis (SAS proc
discrim) conducted to explore the relationships between the
clinically diagnosed male infertility and sperm quality parameters.
(PDF)
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FILE S1 - SUPPLEMENTAL INFORMATION 
 
 
 
Figure S1: Western blotting of SPTRX3 in semen of three ART patients and three presumed 
fertile donors (semen parameters are shown in Table S10). Relative levels of SPTRX3 (top 
panel) and beta-tubulin (loading control; middle panel) are shown for three presumably fertile 
sperm bank donors with acceptable clinical semen parameters (lanes 1-3) and three 
teratozoospermic infertile men (lanes 4-6) suffering from dysplasia of the fibrous sheath. 
Diagram of SPTRX3/tubulin band density ratios is shown on the bottom. Note the high density 
of SPTRX3 band in donor #1, who was presumed fertile.  
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Figure S2: Smoking has a modest effect on sperm SPTRX3 levels. Heavy smokers consuming 
15-30 cigarettes per day had higher average levels of sperm SPTRX3 than other groups shown. 
Of note, two thirds (10/15) of these heavy smokers had indication/clinical diagnosis of male 
infertility. The numeric difference between smokers consuming 2-5 cigarettes per day and 
smokers consuming 15-30 cigarettes per day, was not statistically significant (p>0.1).  
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Figure S3: Scatter diagram illustrating the relationship between subjective, light microscopic 
assessment of sperm SPTRX3 content (% spermatozoa with SPTRX3-positive heads; x-axis) 
and flow cytometry (%M3 SPTRX-value; y-axis). This simple light microscopic analysis was 
conducted as a potential precursor of a test suitable for clinical andrology laboratories. Samples 
from 150 randomly chosen donors, processed for flow cytometry, were re-evaluated by 
epifluorescence microscopy for the percentage of SPTRX3 positive sperm heads, sperm tails, 
and total % of SPTRX3 positive spermatozoa. Correlations were found between all three 
categories of light microscopic evaluation and % of SPTRX3-positive spermatozoa as measured 
by flow cytometry (%M3). The highest correlation coefficient (r=0.46) was between % SPTRX3-
positive sperm heads by light microscopy and %M3 SPTRX3 by flow cytometry (see 
Supplemental Table 4 B). 
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Materials & Methods for Western Blotting and Computerized Densitometry  
 
Western blotting was performed to validate the SPTRX3 antibody and to explore the 
relationship between the total amount of SPTRX3 in spermatozoa of men with good and poor 
clinical semen parameters.  As described previously [36], semen samples were washed, 
extracted in 50 mM Tris HCl, 500 mM NaCl, 0.5% Triton X-100, 1 mM dithiothreitol, 1 mM 
phenylmethylsulfonyl fluoride, and a 1:1,000 dilution of protease inhibitor cocktail (chymostatin, 
leupeptin, antipain, and pepstatin A; Sigma, St. Louis, MO, USA), and boiled for 3 min and  
loading on a 4-15% gradient tris-glycine gel (Bio-Rad Laboratories, Hercules, CA, USA). Protein 
load per lane was 30 µg.  Five microliters of ProSieve® Color Protein Markers (Cambrex, East 
Rutherford, NJ, USA) diluted in 5 µl of loading buffer were used as the molecular mass marker. 
Electrophoresis was performed for one hour using the Fischer Bioscience vertical 
electrophoresis system. After electrophoresis, proteins were transferred to a polyvinylidene 
fluoride (PVDF) membrane (Millipore Corp., Bedford, MA, USA) using a wet transfer system 
(Owl Scientific, Inc., Woburn, MA, USA). The membrane was washed in 0.25% Tris Base Saline 
(TBS)-Tween 20, five times for 4 min on a platform rocker (Barnstead International, Dubuque, 
IA, USA). The membrane was then incubated for one hour in 0.25% TBS-Tween 20 and 10% 
non-fat dried milk for blocking of non-specific antibody binding, washed and incubated overnight 
with anti-SPTRX3 antibody diluted 1:2,000. On the second day, the membrane was washed and 
incubated for 1 hr with GAR-IgG HRP (Invitrogen-Zymed) in 0.25% TBS-Tween 20 and 5% non-
fat dried milk.  The membrane was washed, incubated for 5 min in SuperSignal® West Pico 
Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL, USA), and developed on 
Kodak BioMax Light Film (Kodak, New Haven, CT, USA) for 30 sec using a Hope Micro-Max 
table-top film processor (Hope, Warminster, PA, USA). The membrane was then stripped and 
re-probed overnight with mouse monoclonal antibody E7, recognizing beta tubulin (TUBB) 
(Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), diluted 1:2,000, 
followed by washing and incubation with goat anti-mouse IgG-HRP, serving as a loading control 
and densitometric standard.  Densitometry was performed by the Kodak Electrophoresis 
Documentation and Analysis System 290 (EDAS 290) with image capture by the Kodak DC 290 
camera. Image analysis was performed by Kodak 1D Image Analysis software (Kodak Scientific 
Imaging Systems, New Haven, CT, USA) and the relative densities were entered in MS-Excel to 
calculate the SPTRX3-TUBB ratio for each sample.  
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TABLE S1: Receiver Operator Characteristic (ROC) analysis. As anticipated, Specificity 
increases at the expense of Sensitivity as the cutoff values increase. The area under the ROC 
curve is 0.74, which shows that the %M3 performs well for predicting the male infertility. 
 
Cutoff 
for %M3  
Number of 
men with 
%M3 above 
cutoff 
TRUE 
Positive 
(TP) 
TRUE 
negative 
(TN) 
False 
negative 
(FN) 
False 
Positive 
(FP) 
Sensitivity 
TP/ 
(TP+FN) 
Specificity 
TN/ 
(TN+FP) 
50.0% 0 0 146 93 0 0.0% 100.0% 
35.0% 7 6 145 87 1 6.5% 99.3% 
32.5% 10 9 145 84 1 9.7% 99.3% 
30.0% 16 13 143 80 3 14.0% 98.0% 
27.5% 21 17 142 76 4 18.3% 97.3% 
25.0% 30 23 139 70 7 24.7% 95.2% 
22.5% 38 30 138 63 8 32.3% 94.5% 
20.0% 46 34 134 59 12 36.6% 91.8% 
17.5% 56 39 129 54 17 41.9% 88.4% 
15.0% 79 49 116 44 30 52.7% 79.5% 
12.5% 110 63 99 30 47 67.7% 67.8% 
10.0% 166 80 60 13 86 86.0% 41.1% 
7.5% 197 88 37 5 109 94.6% 25.3% 
5.0% 223 90 13 3 133 96.8% 8.9% 
2.5% 239 93 0 0 146 100.0% 0.0% 
 
 
 
 
True positive (TP) = number of couples ABOVE cutoff 
value who were diagnosed with male infertility (MIF), 
including couples with combined male & female 
infertility    
True negative (TN) = number of couples BELOW 
cutoff who did NOT have MIF diagnosis      
False negative (FN) = number of couples BELOW 
cutoff who were diagnosed with MIF      
False positive (FP) = number of couples ABOVE 
cutoff who were NOT diagnosed with MIF     
Sensitivity = TP/(TP+FN) = percentage of men who 
were diagnosed with MIF that test positive for the 
SPTRX3.    
Specificity = TN/(TN+FP) = percentage of men who 
don’t have MIF diagnosis that test negative for the 
SPTRX3    
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TABLE S2: Semen SPTRX3 levels and live births. 
 
TABLE S2A: 
Pregnancy outcome n %M3 SPTRX3 Number treated 
by ICSI (%) 
Miscarriage – all couples 10 14.8 +/- 2.2 6 (60%) 
Singleton – all couples 34 15.3+/-1.6 19 (56%) 
Twins - all couples 12 10.5 +/- 1.4 7 (58%) 
    
Miscarriage - male inf. couples 3 19.8+/-4.0 3 (100%) 
Singleton - male inf. couples 16 18.2+/-2.7 15 (94%) 
Twins - male inf. couples 3* 14.5+/-2.5 3 (100%) 
 
Pregnancy outcomes were available for 57/60 pregnant couples. One of those 57 pregnancies 
was an ectopic pregnancy in a case of female-only infertility; it is not included in the above table. 
Live birth was achieved in 81% (46/57) of those analyzed pregnant couples.  
*One of those three male factor patients had a vasectomy 
 
 
TABLE S2 B: 
 
Outcome/% M3 SPTRX3 <5% 5-9.99% 
10-
14.99% >15% TOTAL 
Miscarriage – all couples 
0 (0%)  2 (20%)  3 (30%) 
 5  
(50 %) 10 
Singleton – all couples 
3 (9%) 7 (21%) 10 (29%) 14 (41%)  34 
Twins - all couples 
 2 (17%) 3 (25%)   5 (41%)  2 (17%) 12 
All live birth couples 5 (9%) 10 (18%) 15 (26%) 16 (27%) 56 
All pregnant couples 5 (8%)  13 (22%) 21 (35%)  21 (35%) 60 
All non-pregnant couples 
12 (7%) 44 (25%) 66 (35%) 57 (32%) 179 
ALL couples  
17 (7%) 57 (24%) 87 (35%) 78 (33%) 239 
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TABLE S3: Parameters of zygotic development in 239 couples divided into subgroups based on percentages of SPTRX3-positive 
spermatozoa (A) or clinical indication (B). SPTRX3 values, but not the clinical indication, were predictive of good zygotic 
development after IVF or ICSI. Couples with lowest SPTRX3 levels (A, top row, <5% M3) produced the highest percentage of normal, 
two-pronuclear (2 PN) zygotes out of all fertilized oocytes (A, column 8), and also when calculated based on all oocytes harvested (A, 
column 9). These couples also produced the most embryos suitable for transfer or cryopreservation (column 13). Note that couples 
with low or medium levels of SPTRX3 produced more 2PN zygotes per couple on average than couples with >15% SPTRX3 (A, 
column 10). Idiopathic couples in which men recorded more than 15% SPTRX3-positive spermatozoa had the lowest yields of two-
pronuclear zygotes. Numbers shown in red are highest & lowest values for each column. No significant correlations were found 
between parameters of early embryo development and flow cytometric SPTRX3 levels.  
 
TABLE S3A: Parameters of pronuclear development in couples with varied sperm SPTRX3 content 
 
Column  1 2 3 4 5 6 7 8 9 10 11 12 13 
%M3 
SPTRX3 
n -
couple
s 
Total 
oocytes 
matured 
Total 
oocytes 
fertilized 
Total 
polypronu
clear 
zygotes 
(%) 
Total 0 
PN 
zygotes 
(%) 
Total 1 
PN 
zygotes 
(%) 
Total 2 PN 
zygotes 
produced (% 
of fertilized 
oocytes) 
% 2 PN 
zygotes 
produced 
out of all 
harvested 
oocytes 
Avg. 
number of 
2PN 
zygotes 
produced  
per couple 
Embryos 
transferred 
(% out of all 2 
PN zygotes) 
Embryos 
cryo-
preserved 
(out of all 2 
PN zyg) 
% 
Embryos 
transferred 
and cryo-
preserved 
out of all 2 
PN zygotes  
<5% 16 167 159 9 9 4 137 (86.2%) 82.0% 8.6 30 (21.9%) 84 (61.3%) 83.2% 
5-9.99% 57 732 665 45 78 30 512 (77.0%) 69.9% 9.0 123 
(24.0%) 
268 
(52.3%) 
76.3% 
10-14.99% 88 995 793 36 103 39 615 (77.6%) 61.8% 7.0 174 (28.3%) 319 
(52.3%) 
80.6% 
>15% 78 871 679 25 65 26 563 (82.9%) 64.6% 7.2 164 (29.1%) 258 
(45.8%) 
74.9% 
>15% 
idiopathic 
12 148 109 6 25 2 76 (69.7%) 51.4% 6.3 25(16.9%) 38 (50.0%) 66.9% 
 
TABLE S3B: Lack of influence of clinical indication on parameters of pronuclear development  
 
Male Inf. 72 818 654 25 34 23 572 (87.5%) 69.9% 7.9 162 (28.3%) 301 
(52.6%) 
80.9% 
Female Inf. 
 
85 963 899 59 131 51 658 (73.2%) 68.3% 7.7 168 (25.5%) 342 
(52.0%) 
77.5% 
Combined 
Inf. 
 
21 283 220 3 12 4 201 (91.4%) 71.0% 9.6 39 (19.4%) 98 (48.8%) 68.2% 
Idiopathic 
Inf. 
61 728 584 28 83 21 452 (77.4) 62.1% 7.4 127 (28.1%) 220 
(48.7%) 
76.8% 
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TABLE S4: Relationship between the clinical treatment assignment and various sperm quality 
parameters. 
 
Parameter p-value Odds ratio* 
V 
PR 
NX 
NEC 
M 
C 
  0.8554 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
   NA 
1.176 
1.067 
0.936 
1.142 
1.029 
Median ALL 
Median M3 
Median M2 
Median M1 
Mean all 
Mean M3 
Mean M2 
Mean M1 
Total 
%M3 
%M2 
%M1 
CVALL 
CVM3 
CVM2 
CVM1 
  0.0125 
<0.0001 
  0.3114 
  0.0022 
<0.0001 
<0.0001 
  0.3920 
  0.0001 
<0.0001 
<0.0001 
<0.0001 
  0.4735 
  0.0014 
  0.0357 
  0.0342 
  0.0006 
 0.964 
 0.978 
    NA 
 5.187 
 0.960 
 0.972 
     NA 
34.058 
 1.088 
 0.904 
 1.141 
     NA 
 0.994 
 0.99 
 0.931 
 0.837 
   
 
 
 
Abbreviations: 
C=sperm count 
V=semen volume 
M=total motility 
PR=progressive motility  
NX=morphology/ % normal spermatozoa 
NEC=percent of necrotic spermatozoa assessed by Williams test 
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TABLE S5 A: Pregnancy rates in 150 infertile couples, divided by percentages of SPTRX3-
positive spermatozoa. In accordance with flow cytometric SPTRX3-data, couples with lowest 
levels of SPTRX3 had highest pregnancy rate (column 2). Also similar to flow cytometric results, 
the percentage of couples treated by ICSI increased progressively with sperm SPTRX3 content 
(column 6). Spermatozoa were evaluated for the presence of SPTRX3 in the sperm head (B) or 
tail (C; combined head and tail labeling has not been observed), adding up to third category of 
total SPTRX3-positive spermatozoa (A). Numbers shown in red are highest & lowest values for 
each column. With the exception of one SPTRX3 parameter (A-% of all positive spermatozoa), 
pregnancy rates (column #2) in light microscopic analysis were dose-dependent on SPTRX3 
values.  
 
Column # 
 
1 2 3 4 5 6 
Parameter N 
(couples) 
% pregnant 
(n) 
% male & 
combined 
infertility 
cases in 
this group 
(n) 
Avg. %2 PN 
zygotes per 
couple out of 
all ovulated 
(n/total) 
Avg. %2 PN 
zygotes per 
couple out of 
all fertilized 
% treated 
by ICSI 
 
A-% of all positive spermatozoa (head-positive and tail-positive, combined) 
 
<5% 30 37% (11) 13% (4)  59.5% 
(235/395) 
79.1% 
(235/297) 
267% 
(8/30) 
5-9.99% 73 29% (23) 19% (14) 49.3% 
(500/1014) 
74.9%  
(500/668) 
48% 
(35/73) 
10-14.99% 29 18% (5) 38% (11) 59.2% 
(252/426) 
83.7% 
(252/301) 
59% 
(17/29) 
>15% 18 22% (4) 56% (10) 58.7% 
(125/213) 
89.9% 
(125/139) 
72% 
(13/18) 
All couples 150 29% (43) 26% (39) 54.3% 
(1112/2048) 
79.2% 
(1112/1405) 
49% 
(73/150) 
 
B-% of head only-positive spermatozoa 
 
<5% 103 33% (34) 19%(20) 53.6% 
(764/1417) 
75.2% 
(764/1016) 
44% 
(44/103) 
5-9.99% 41 20% (8)  39% (16) 52.8% 
(299/566) 
88.7% 
(299/337) 
63% 
(26/41) 
>10% 6 17% (1) 50% (3) 75.5% (49/65) 94.2% (49/52) 50 % (3/6) 
 
C-% of tail only-positive spermatozoa 
 
<5% 93 33% (31) 16% (15) 51.3% 
(667/1301) 
75.9% 
(667/879) 
38% 
(35/93) 
5-9.99% 46 22%(10) 39% (18) 59.7% 
(382/640) 
84.0% 
(382/455) 
70% 
(32/46) 
>10% 10 20% (2) 60% (6) 58.9% 
(63/107) 
88.7% (63/71) 60% (6/10) 
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TABLE S5 B: Correlations between light microscopic SPTRX3-evaluation (STIX assay) and % 
of SPTRX3-positive spermatozoa as measured by flow cytometry. Bold font indicates highest 
correlation coefficients for flow cytometric and light microscopic parameters. 
 
 % Tail %Head %H&T %M1 %M2 %M3 
% Tail 1      
%Head 0.71 1     
%H&T 0.94 0.91 1    
%M1 -0.29 -0.27 -0.31 1   
%M2 -0.25 -0.41 -0.35 0.08 1  
%M3 0.33 0.46 0.42 -0.41 -0.94 1 
 
Abbreviations: 
 
% Tail=spermatozoa with SPTRX3 labeling in the sperm tail midpiece 
%Head: spermatozoa with SPTRX3-labeling in the sperm head (mostly nuclear vacuoles) 
%H&T=Combined % of spermatozoa carrying SPTRX3 in either sperm head or tail 
%M1=% spermatozoa gated within marker M1 in flow cytometric histograms  
%M2=% spermatozoa gated within marker M2 in flow cytometric histograms  
%M3=% spermatozoa gated within marker M3 in flow cytometric histograms  
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 Table S6: Sperm SPTRX3 levels and oocyte quality parameters in 238 couples divided by 
female partners’ age, with the threshold of 35 years of age. Female age subgroups (in rows) 
were further divided based on male partners’ semen content of SPTRX3-positive spermatozoa 
(Column 4), and based on the treatment (IVF or ICSI, columns 6 & 7). Regardless of female 
partner’s age, the combined IVF & ICSI pregnancy rates (column 9) as well as the ICSI 
pregnancy rates (column 10) were numerically higher when the male partner had <10% 
SPTRX3-positive spermatozoa. 
 
1 2 3 4 5 6 7 8 9 10 
Female 
age 
Avg. male 
age  
Avg. % 
M3 
SPTRX3 
Threshold  
% M3 
SPTRX  
n Treated 
by IVF  
Treated 
by ICSI 
(%) 
Mature 
oocytes 
total 
(per 
couple) 
Pregnant 
couples 
IVF & 
ICSI (%) 
Pregnant 
ICSI 
couples 
35 
years or 
younger 
 
n=140 
33.2±0.36 14.3±0.75 <10 48 30** 21 
(43%) 
693 
(14.1) 
18/48 
(38%) 
9/21 
(43%) 
>10 93 35*** 60 
(65%) 
1193 
(12.8) 
23/93 
(25%) 
18/60 
(30%) 
Older 
than 35  
n=99 
40.7±0.6 14.4±0.83 <10 25 20 5 
(20%) 
206 
(8.24) 
6/25 
(24%) 
2/5 
(40%) 
>10 74 30**** 45 
(61%) 
673 
(9.1) 
13/74 
(18%) 
7/45 
(16%) 
 
*Age information was not provided for one female patient 
**Three couples were first treated by IVF before ICSI 
***Three couples were first treated by IVF before ICSI  
****One couple was first treated by IVF before ICSI 
 
 
  
12 
 
TABLE S7: Analysis of subgroups divided by indication (male or female infertility) and female 
age. Combined and idiopathic cases were not included in analysis. 
 
 
A. Female infertility couples 
 
Age 
female 
Avg. % M3 Avg. Male 
age 
% 
M3  
n Treated 
by IVF 
Treated 
by ICSI 
(%) 
Mature 
oocytes 
total (per 
couple) 
Pregnant 
couples 
IVF & ICSI 
(%) 
Pregnant  
ICSI 
couples 
35 yr 
or 
less 
10.5±0.8 41.0 ±1.0 <10 24 23 1 
(4.3%) 
326 
(13.6) 
7 
(30.4%) 
0 (0%) 
>10 22 17 5 
(22.7%) 
278 
(12.6) 
7 
(31.8%) 
2 (40%) 
>35 yr 12.5±1.2 32.8±0.6 <10 12 11 1 
(8.3%) 
93 (7.8) 4 
(33.3%) 
1 (100%) 
>10 27 19 8 
(29.6%) 
213 
(7.9) 
10 
(37.0%) 
1 
(12.5%) 
 
B. Male infertility couples 
 
Age 
female 
Avg. % M3 Avg. Male 
age 
% 
M3  
n Treated 
by IVF 
Treated 
by ICSI 
(%) 
Mature 
oocytes 
total (per 
couple) 
Pregnant 
couples 
IVF & ICSI 
(%) 
Pregnant  
ICSI 
couples 
35 yr 
or 
less 
18.3±1.6 33.4±0.7 <10 9 0* 9 
(100%) 
131 
(14.6) 
2 
(22.2%) 
2 
(22.2%) 
  >10 37 0** 37 
(100%) 
448 
(12.1) 
4 
(10.8%) 
4 
(10.8%) 
>35 yr 19.4±1.7 41.0±1.0 <10 0 0 0 (0%) 0 (0) 0 (0%) 0 (0%) 
  >10 26 2 24 
(92.3%) 
239 
(9.2) 
8 
(30.8%) 
7 
(29.2%) 
 
*Two couples were first treated by IVF before ICSI 
**One couple was first treated by IVF before ICSI 
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TABLE S8: Correlations between flow cytometric SPTRX3 values and clinical semen 
parameters. R-values by Person’s correlation analysis are shown. Most significant values are 
printed bold. In general, SPTRX3 values correlate negatively with sperm count, motility, and 
percentage of morphologically normal spermatozoa in samples, assessed by conventional light 
microscopic semen evaluation. Ratio of spermatozoa to debris (%TOTAL) correlates positively 
with sperm count, motility and normal morphology. Bold font indicates highest correlation 
coefficients. 
 
 
Sorted by  Clinical Parameter  Correlation 
with %M3 
Correlation 
with %TOTAL 
Correlation with 
GeoMean M3 
A-None All patients 
n=239 
Sperm count -0.37 0.58 -0.55 
% live sperm. 0.30 -0.19 0.23 
% prog. motile sperm. -0.42 0.34 -0.42 
% total motile sperm. -0.43 0.45 -0.46 
% normal sperm. -0.35 0.30 -0.33 
 
B-Indication: Male infertility 
n=72 
Sperm count -0.24 0.38 0.28 
% live sperm. -0.09 -0.30 -0.26 
% prog. motile sperm. 0.19 0.29 0.20 
% total motile sperm. 0.18 0.24 0.09 
% normal sperm. -0.04 0.20 -0.06 
Female 
infertility n=85 
Sperm count -0.17 0.46 -0.38 
% live sperm. 0.08 -0.07 -0.02 
% prog. motile sperm. -0.15 0.19 -0.19 
% total motile sperm. -0.14 0.24 -0.19 
% normal sperm. -0.17 0.32 -0.21 
Combined 
infertility n=61 
Sperm count 0.02 0.80 -0.46 
% live sperm. 0.04 -0.35 0.45 
% prog. motile sperm. 0.01 0.39 -0.42 
% total motile sperm. -0.17 0.39 -0.63 
% normal sperm. -0.21 0.02 -0.13 
Idiopathic 
infertility n=21 
Sperm count 0.35 0.19 -0.10 
% live sperm. -0.07 -0.18 -0.11 
% prog. motile sperm. -0.02 0.25 0.27 
% total motile sperm. -0.05 0.27 0.34 
% normal sperm. 0.23 0.04 -0.04 
 
C-Pregnancy Pregnant n=60 Sperm count -0.31 0.25 -0.22 
% live sperm. 0.09 -0.24 0.27 
% prog. motile sperm. -0.30 0.48 -0.44 
% total motile sperm. -0.32 0.46 -0.42 
% normal sperm. -0.29 0.33 -0.29 
Non-pregnant 
n=179 
Sperm count -0.32 0.09 -0.06 
% live sperm. 0.31 -0.23 0.22 
% prog. motile sperm. -0.36 0.26 -0.23 
% total motile sperm. -0.38 0.30 -0.26 
% normal sperm. -0.32 0.19 -0.10 
 
D-Pregnancy and 
clinical indication 
Female-
pregnant 
Sperm count -0.26 0.64 -0.53 
% live sperm. -0.06 -0.15 0.08 
% prog. motile sperm. -0.24 0.25 -0.31 
% total motile sperm. -0.28 0.26 -0.40 
% normal sperm. -0.29 0.55 -0.48 
Female non-
pregnant 
Sperm count -0.13 0.40 -0.34 
% live sperm. 0.14 -0.04 -0.07 
% prog. motile sperm. -0.08 0.15 -0.12 
% total motile sperm. -0.01 0.21 -0.06 
% normal sperm. -0.09 0.22 -0.11 
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Combined 
pregnant 
Sperm count 0.64 0.72 -0.52 
% live sperm. -0.22 -0.37 0.22 
% prog. motile sperm. 0.05 0.18 -0.92 
% total motile sperm. 0.22 0.36 -0.87 
% normal sperm. -0.37 -0.26 -0.22 
Combined non-
pregnant 
Sperm count -0.13 0.85 -0.54 
% live sperm. 0.12 -0.50 0.59 
% prog. motile sperm. 0.01 0.60 -0.39 
% total motile sperm. -0.28 0.55 -0.60 
% normal sperm. -0.21 0.18 -0.14 
Male-pregnant Sperm count -0.32 0.45 -0.37 
% live sperm. 0.21 0.45 0.01 
% prog. motile sperm. -0.27 -0.28 0.05 
% total motile sperm. -0.24 -0.23 0.16 
% normal sperm. -0.22 -0.30 0.20 
Male-non-
pregnant 
Sperm count -0.24 0.47 -0.42 
% live sperm. 0.32 -0.26 0.08 
% prog. motile sperm. -0.35 0.02 -0.21 
% total motile sperm. -0.27 0.16 -0.08 
% normal sperm. -0.14 0.06 -0.14 
Idiopathic-
pregnant 
Sperm count -0.50 0.20 -0.67 
% live sperm. 0.04 0.14 -0.45 
% prog. motile sperm. -0.63 0.22 -0.27 
% total motile sperm. -0.57 0.26 -0.32 
% normal sperm. -0.57 0.12 -0.15 
Idiopathic-non-
pregnant 
Sperm count -0.29 0.50 -0.52 
% live sperm. 0.26 -0.05 0.24 
% prog. motile sperm. -0.25 -0.02 -0.08 
% total motile sperm. -0.25 0.20 -0.27 
% normal sperm. -0.15 0.01 -0.04 
 
E-Treatment IVF n=98 Sperm count -0.20 0.46 -0.34 
% live sperm. 0.04 -0.03 -0.04 
% prog. motile sperm. -0.14 0.04 -0.05 
% total motile sperm. -0.14 0.21 -0.08 
% normal sperm. -0.17 0.16 -0.12 
ICSI n=131 Sperm count -0.32 0.51 -0.52 
% live sperm. 0.31 -0.10 0.19 
% prog. motile sperm. -0.36 0.23 -0.34 
% total motile sperm. -0.37 0.33 -0.37 
% normal sperm. -0.28 0.14 -0.20 
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TABLE S9: Spearman correlations between the most informative flow cytometric SPTRX3 
parameters and the conventional semen parameters (the second numbers in the cells are the p-
values). 
 
 M PR NEC NX C 
MeanM1   0.40  
<0.0001       
  0.39 
<0.0001 
 -0.24   
<0.0001 
  0.27 
<0.0001 
  0.32 
<0.0001 
MedianM1   0.37 
<0.0001 
  0.36  
<0.0001      
 -0.23  
  0.0004                         
  0.24 
  0.0002 
  0.26 
<0.0001 
CVM1  -0.35 
<0.0001 
 -0.35      
<0.0001   
  0.24  
<0.0001           
 -0.23 
  0.0002              
 -0.28 
<0.0001 
%M2   0. 50                              
<0.0001               
  0.48                                 
<0.0001             
 -0.34                             
<0.0001                   
0.36                        
<0.0001         
  0.48                              
<0.0001         
%M3  -0.45                                  
<0.0001            
-0.43                                 
<0.0001              
0.31
<0.0001             
 -0.32                               
<0.0001         
-0.41                               
<0.0001         
 
 
Abbreviations: 
C=sperm count 
V=semen volume 
M=total motility 
PR=progressive motility  
NX=morphology/ % normal spermatozoa 
NEC=percent of necrotic spermatozoa assessed by Williams test 
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TABLE S10: Conventional semen parameters for semen samples used for Western blotting. 
 
 
 PRESUMED FERTILE DONORS DIAGNOSED, TERATOSPERMIC 
MALE INFERTILITY PATIENTS 
SAMPLE 
NUMBER 
1 2 3 4 5 6 
SPERM COUNT 
(x106) 
117 143 205 18 54 44 
% MOTILE 60 70 65 0.2 0.9 20 
% MORPHOL. 
DEFECTS 
28 22 26 97 98 87 
AGE 20 27 23 26 33 34 
SPTRX3/TUBB 
RATIO 
1.34 0.26 0.23 0.85 0.98 1.42 
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Supplemental Statistical Information  
(Discriminant Function Analysis)  
 
 
ANALYSIS I: Discriminant analysis using SAS PROC discrim and stepdisc procedures 
was applied to study the relationship of pregnancy rate with the sperm quality 
parameters and SPTRX3 levels, with consideration of treatment assignments.  
 
SAS proc discrim procedure was applied to conduct discriminant analysis to understand the 
relationship between the pregnancy rate and all the sperm quality parameters. When all data is 
considered and all sperm quality parameters are considered, there is no significant discriminant 
function. The stepwise discriminant analysis identifies one significant predictor, PR, which leads 
to a discriminant function with canonical correlation of 0.13 (p-value=0.05).  The cross-validated 
classification accuracy rate based on this discriminant function is 75%. The PR variable 
separates the two groups well with mean value of 21.6 for the non-pregnant group and 24.8 for 
the pregnant group.  
 
When considering the IVF group only, no significant discriminant function is detected when all 
sperm quality parameters are considered. The stepwise discriminant analysis identifies Volume 
and M2% as significant predictors and the discriminant function based on these two variables is 
significant with p-value=0.008 and has canonical correlation of 0.3. The discriminant function is 
highly positively correlated with M2% (r=0.71) and negatively correlated with Volume (r=-0.68). 
The cross-validated classification accuracy rate of this discriminant function is 73%. The means 
of M2% are 81.4 versus 84.2 for non-pregnancy group and pregnant group, respectively. The 
volume has mean 3.4 for non-pregnancy group and 2.8 for pregnancy group.  
 
When considering the ICSI treatment group only, the stepdisc procedure identified four 
predictors: V, PR, M and C. The discriminant function based on these four predictors has p-
value=0.014 and canonical correlation of 0.31. The cross-validated classification accurate rate 
is 78%. The structure matrix shows that this discriminant function is positively correlated with C 
(r=0.52) and negatively correlated with V (r=-0.5). The C variable separates the two groups well 
with 44.9 (non-pregnancy group) versus 26.7 (pregnancy group). The V variable has mean of 
3.1 (no pregnancy) versus 3.6 (pregnancy).   
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If only the biomarker parameters are considered, the discriminant analysis identified %M2 and 
CVM3 as significant predictors for the IVF group (Table S11). The discriminant function has p-
value 0.025 with canonical correlation of 0.26. It has positive correlation with %M2 (r=0.82) and 
CVM3 (r=0.77). The cross validated classification accuracy rate is 72% and the two 
variables %M2 and CVM3 separates the pregnancy group from the no-pregnancy group well.  
 
If only the biomarker parameters are considered, the discriminant analysis identified Median M3 
as a significant predictor for the ISCI group. The discriminant function has p-value 0.05 with 
canonical correlation of 0.17. The cross validated classification accuracy rate is 80% and the 
variable Median M3 separates the pregnancy group from the no-pregnancy group well with 
means of 232 versus 212 for the two groups.  
 
 
TABLE S11: 
 
Pregnancy                                  Obs Variable N   Mean Std Dev         Minimu
m   
Maximum 
 
  YES                      75 %M2          75   81.43       6.33      47.92 89.43 
                                 CVM3 75 156.85      27.76      89.42     230.44 
  NO                            32 %M2 32 84.18       4.03      72.95      89.42 
                               CVM3 32   169.81      31.11      98.96     258.01 
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ANALYSIS II: Discriminant analysis was conducted to study the relationship of the 
treatment assignment, SPTRX3 and the sperm quality parameters. SAS proc discrim 
procedure was used to conduct discriminant analysis to study the relationship between 
the treatment assignment and the sperm quality parameters. 
 
The discriminant function is highly significant (p<0.0001) with canonical correlation of 0.67. The 
structure matrix in TABLE S12 shows that the discriminant function is positively correlated with 
PR (0.78), C (0.62), M (0.59) NX (0.54), % Total (0.48), %M2% (0.43) and negatively correlated 
with Mean M3 (-0.5), Median M3 (-0.43), NX (% normal sperm) (-0.39) and %M3 (-0.37). The 
cross-validated classification accuracy rate based on this discriminant function is 80%. Note that 
the above 10 predictors include the same nine predictors in the analysis of male infertility 
indicators besides the NX variable.  
 
TABLE S12:  Pooled Within Canonical Structure 
 
                                Variable                   Can1 
 
                                M1                        -0.041339 
                                M2                         0.431106 
                                M3                        -0.369862 
                                Total                      0.478822 
                                Meanall                -0.259177 
                                MeanM1                0.294226 
                                MeanM2               -0.067757 
                                MeanM3               -0.503966 
                                CVall                     -0.226949 
                                CVM1                    -0.251488 
                                CVM2                    -0.143186 
                                CVM3                    -0.134124 
                                MedianALL            -0.197052 
                                MedianM1               0.226282 
                                MedianM2              -0.080284 
                                MedianM3              -0.432187 
                                V                             0.023715 
                                C                             0.616992 
                                NEC                       -0.390293 
                                M                             0.588741 
                                PR                           0.779281 
                                NX                           0.544063 
Abbreviations: C=sperm count; V=semen volume; M=total motility; PR=progressive motility; 
NX=morphology/ % normal spermatozoa; NEC=percent of necrotic spermatozoa assessed by 
Williams test 
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TABLE S13 gives the means of the ten variables by the treatment groups and shows that the 
ten variables separate the two groups well. For instance, %M2 has a mean of 82.25 for the IVF 
group and a mean of 76.41 for the ICSI group. 
 
Table S13: 
                                     
                    Treatment    Obs    Variable                 Mean       N 
                    ---------------------------------------------------------------- 
                      IVF              107    %M2                82.2496262     107 
                                                    %M3                11.3400935     107 
                                                    Total                 89.8795327    107 
                                                  MeanM3         229.6221495    107 
                                         MedianM3      184.2907477    107 
                                          C                       95.7102804    107 
                                          NX                     24.4439252    107 
                                                    M                       47.5981308     107 
                                        PR                     29.2523364     107 
                                         NX                     49.8773585      106 
 
                    ICSI              131    %M2                 76.4079389    131 
                                            %M3                 16.8411450    131 
                                                   Total                 80.2452672    131 
                                                   MeanM3         274.9711450    131 
                                                   MedianM3       215.6846565    131 
                                                   C                        41.1854962    131 
                                                   NX                     32.1267717    127 
                                                   M                       34.6564885    131 
                                                  PR                      16.5590551    127 
                                                  NX                      34.1111111    126 
-------------------------------------------------------------------------------------------------------------------------- 
Abbreviations: C=sperm count; V=semen volume; M=total motility; PR=progressive motility; 
NX=morphology/ % normal spermatozoa; NEC=percent of necrotic spermatozoa assessed by 
Williams test 
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ANALYSIS III: Logistic regression analysis using SAS proclogistic procedure was 
applied to study the relationship of pregnancy rate with the sperm quality parameters 
with consideration of female age and treatment assignments.  
 
Considering only the patients assigned to the IVF treatment, both %M2 SPTRX3 and %M3 
SPTRX3 were significant predictors for pregnancy rate, with or without adjustment for the 
female age factor.  None of the convention parameters or other flow cytometric parameters was 
significant even with adjustment for the female age.  The odds of getting pregnant in the IVF 
group were reduced by 10.2% for every unit of increase in %M3 (p-value=0.03).  After adjusting 
for the factor of female partner’s age (35 years or younger vs. older than 35), the odds of getting 
pregnant in the IVF group were reduced by 11.1% for every unit of increase in %M3 (p-
value=0.03). The odds of getting pregnant when %M3 was below 5% were 6.7 times better  
than for the %M3 levels above 15% (p-value=0.05). After adjusting for female age, the adjusted 
odds ratio was 7.5 with p-value=0.04. We found that %M2 was also a significant predictor for 
pregnancy rate for IVF group with p-value=0.03 and the odds ratio is 1.1 for each unit increase. 
After adjusting for the female age, the p-value=0.02 and the odds ratio was 1.1 (i.e. the odds of 
getting pregnant in IVF group increased by 13.6% for every unit increase of %M2).   
 
For the ICSI group, the pregnancy rate was not affected by any of the new or conventional 
sperm quality parameters or the female age factors. When considering all patients 
together, %M3 and %M2 were not significant predictors for pregnancy rate (p-value=0.38 and 
0.50 respectively). However, when we considered categorizing the %M3 levels into four groups, 
below 5%, between 5-10%, between 10-15%, and above 15% SPTRX3-positive spermatozoa, 
the estimated odds ratio between the  below 5% group and the above 15% group was 2.94 with 
p-value=0.06. In other words,  the odds of getting pregnant  when the SPTX3 levels was below 
5% were 2.94 times better than that for the SPTX3 levels above 15%.  After adjusting for female 
age, the adjusted odds ratio for the below 5% SPTX3 group over the above15% SPTX3 group 
was 3.3 with p-value=0.04. Using 85% as a cutoff for %M2, the below 85% group and above 85% 
group had significantly different pregnancy rate when considering all patients together. The 
odds of getting pregnant for the above 85% of %M2 group were 113.2% better than that for the 
below 85% group (p-value=0.02) and the pregnancy rate was 41.5% versus 22.72%. After the 
adjustment for the female age, the odds ratio was 2.1 with p-value=0.02. 
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ANALYSIS IV: Discriminant analysis using SAS proc discrim procedure was conducted 
to explore the relationships between the clinically diagnosed male infertility and sperm 
quality parameters. Both male-only and combined (female & male) infertility cases are 
considered to be male infertile cases in this analysis of various sperm quality 
measurements including the conventional parameters and the parameters based on 
SPTRX3 analysis by flow cytometry. 
 
SAS proc discrim procedure was used to study the relationship between the male infertility 
indicator variable and all the sperm quality parameters. The discriminant function detected is 
highly significant with p-value<0.0001 and has the canonical correlation of 0.83, which is the 
maximal multiple correlation of the linear combination of the sperm quality parameters with the 
male infertility indicator variable. TABLE S14 (below) presents the canonical structure matrix of 
the discriminant analysis, which shows that the discriminant function is  positively correlated 
with progressive motility (PR; r=0.84), total motility (M; r=0.60) and % normal spermatozoa (NX; 
r=0.46), C (r=0.46), % Total (r=0.35),  %M2 (r=0.33) and negatively correlated with %M3 (r=-
0.29) Mean M3(r=-0.35) and Median M3(r=-0.30). The cross-validated classification accuracy 
rate based on the discriminant function is 90%. TABLE S15 shows means of the above nine 
variables separately for infertile and fertile male. Based on Table 13, all nine variables (PR, M, 
NX, C, % Total, % M2, % M%, Mean M3 and Median M3) clearly separate the two groups. For 
example, PR separates the two groups with a mean of 11.5 for infertile male and 29 for fertile 
male.  %M3 has mean 18.6 for infertile group versus mean 11.6 for the fertile group, which is in 
accordance with the proposed property of SPTRX3 protein as a biomarker specific to defective 
spermatozoa associated with male infertility.  
 
TABLE S14: Canonical structure matrix of the discriminant analysis of the relationship between 
male infertility and sperm quality. 
                            Pooled Within Canonical Structure 
 
                                Variable                   Can1 
 
                                M1                        0.005240 
                                M2                        0.327101 
                                M3                        -0.294292 
                                Total                      0.345735 
                                MeanAll                -0.231519 
                                MeanM1                 0.215277 
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                                MeanM2                -0.118957 
                                MeanM3                -0.349959 
                                CVall                     -0.151343 
                                CVM1                    -0.186697 
                                CVM2                    -0.024542 
                                CVM3                    -0.100571 
                                MedianALL             -0.192479 
                                MedianM1               0.210773 
                                MedianM2              -0.126937 
                                MedianM3              -0.299451 
                                V                              0.021139 
                                C                              0.456325 
                                NEC                        -0.244176 
                                M                             0.601372 
                                PR                           0.841907 
                                NX                           0.458204 
 
 
TABLE S15: Means of the nine variables for infertile male and fertile male 
 
 
Mean 
Infertile male Fertile male 
PR 11.5 29 
M 29.3 47.6 
NX 28.6 49.1 
C 27.2 90.3 
% Total 77.8 88.9 
M2% SPTRX3 78.8 81.8 
M3% SPTRX3 18.6 11.6 
MeanM3 SPTRX3 285.5 234.7 
MedianM3 SPTRX3 223.1 187.7 
Abbreviations: C=sperm count; V=semen volume; M=total motility; PR=progressive motility; 
NX=morphology/% normal spermatozoa  
 
 
 
 
 
 
 
 
 
